Did you happen to google Gbola Amusa and Chardan? Due diligence.....
The chart action today was interesting, with a gap down at the open, but a flat line the rest of the day as there was a struggle between buyers and sellers who could not move the stock much closer to 17. So, I disagree with a thesis of gloom and doom. I agree that the stock move to 18+ was a bit premature, so at this level, we are at 21X earnings, and an eps that was bumped up to .84 from .78 seven days ago. The company is picking up institutional coverage, is profitable, and eps is expected to rocket from .13 to .78 over the coming year. I like the chart action today, and it filled a gap that left us below the all time high, and not by much. I saw a similar chart action back in May in SUPN, and the price recovered.
Insider sales can occur for reasons such as legitimate need, preplanned sales, etc. Investor day is tomorrow, and the CEO already said to expect good news from that. I can't imagine that Supernus will suffer from good news. So, be patient, here, Analysts love the stock, even if it's not Bluebird or other parabolic stocks. It has earnings, and that they're growing. I see the company moving to a proce target of 21, and higher over time.
Valueact specifically stated that they are selling because Valeant has done so welkl that they now make up more than 20% of their holdings. It's called rebalancing due to great performance by Valeant, not some negative reason. Value Act said that Valeant is still one of their largest holdings and will continue to be. I am not sure what the issue is. and why there is panicking?
I was thinking more of the long term chart structure than comparing the two directly, but clearly, Wall Street institutions are noticing, and that is very helpful. :)
I agree...I also like AMAG, and these types of companies do tend to keep moving higher. Another one today that had a huge surge was FOLD, on 11 million in volume.
Supernus has a chart similar to Horizon Pharma, which moved in the same type of trajectory to over $30 per share on increasing revenues and earnings. Supernus is expected to earn .13 in 2015 abd .78 next year, so it's undervalued on an eps basis. Analysts tend to be conservative on estimates, so I expect probably 30+ in the not too distant future, and much higher in a couple of years. I'd also take a look at Agenus if anyone feels he or she missed the boat on Supernus. The fact that it's up on a dpwn market day is significant, and the volumje is probably retail and institutional money getting in on the uprade from Suntrust and previously, Guggenheim. As other firms initiate coverage, we'll see the mid twenties.
Chardan's analyst, Gbola Amusa, is well-known. I suggest you google his name for due diligence. I am taking some steps to address my concerns on the issue, too, because I think the target of 50 is notthing more than an attention seeking ploy.
Chardan attraxtwed the short sellers en masse, and we all know the history behind that. Ironically, Gbola Amusa came from UBS, which has a buy rating on Esperion. Google Gbola Amusa for details.
I love this stock...very much under the radar, and similar to Berkshire. They also have no intention of splitting the shares.
There are always uncounted billionaires on these message boards who make perfect trades :) In their dreams. I agree that AGEN has a great future, with the collaborations it has. i see following the path of Supernus and ultimately Horizon Pharma, if it's not bought out.
If this is true, then contact the SEC, because that is serious, if true.
Then why is Chardan receiving asymetric coverage over the buy side? Thatsuggests favoritism and given the nature of the press to be unbiased, that needs to stop. Has anyone reached out to Chardan? That needs to happen.
If there are regulatory issues here, those need to be addressed and someone needs to accept responsibility.
No-alarmist's view....we'll see what the SEC says when they review what has happened
Eagle is similar to AMAG, by the way, in both eps and chart action. Take a look. I hold the egrx shares and amag options, august, 65 strike..
I think the SEC needs to take a look at the Esperion short selling attacks, and ask the important questions here, so we need to reach out to them. I am weighing my own legal response given the short selling media circus as well. No one should be held hostage by that, or lose money.
I'd like the SEC and concerned investors to address the short attacks against Esperion, and for them also to seek whatever legal steps they need to take to recover losses on that basis.
We heard the same argument of GIlead vs. Abbvie. One pill vs. multiple pills and side effects. Gilead disproved the naysayers. New high today. Pateints would sue companies blocking access to more tolerable drugs. I don't see the issue.
The shorts forget that Roger Newton is associated with Lipitor, and yet they're willing to bet against him with their patsies and various machinations. It's a stupid bet. At some point, their attention seeking predictions will attract attention from the SEC and is that what they want?